Summary This latest Pharmaceutical and Healthcare disease pipeline guide Gingivitis – Pipeline Review, H1 2020, provides an overview of the Gingivitis (Mouth And Dental Disorders) pipeline landscape.
Gingivitis is an inflammation of the gums, usually caused by a bacterial infection. Symptoms include sensitive teeth, pus between teeth and gums, loose teeth, gums that are red, tender, or swollen. Risk factors include diabetes, smoking or chewing tobacco, broken fillings, compromised immunity, and genetic factors. Treatment includes antibiotics.
Report Highlights This Pharmaceutical and Healthcare latest pipeline guide Gingivitis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Gingivitis (Mouth And Dental Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gingivitis (Mouth And Dental Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gingivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Discovery stages are 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 2 molecules, respectively.
Gingivitis (Mouth And Dental Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Gingivitis (Mouth And Dental Disorders). - The pipeline guide reviews pipeline therapeutics for Gingivitis (Mouth And Dental Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Gingivitis (Mouth And Dental Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Gingivitis (Mouth And Dental Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Gingivitis (Mouth And Dental Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Gingivitis (Mouth And Dental Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Gingivitis (Mouth And Dental Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
Foot & Mouth Disease Vaccines Market Research Report by Product (Conventional and Emergency), by Application (Cattle, Goat, Pigs, and Sheep) - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Foot & Mouth Disease Vaccines Market is expected to grow from USD 1,937.58 Million in 2019 to USD 3,085.67...
Smoothened Homolog - Pipeline Review, H1 2020 Summary Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Smoothened Homolog –...
239 pages •
By Asia Market Information & Development Company
• Jun 2020
China’s demand for Liver Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports,...
Pertussis (Whooping Cough) - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Pertussis - Pipeline Review, H1 2020, provides an overview of the Pertussis (Infectious Disease) pipeline landscape. Pertussis, also known as whooping cough, is a...
Bcl 2 Like Protein 1 - Pipeline Review, H1 2020 Summary Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) – Bcl-2-like protein 1 is a protein encoded by the BCL2L1 gene. It belongs to BCL-2 family. It is a potent inhibitor of cell death. It inhibits activation of caspases. It regulate...
Emphysema Global Clinical Trials Review, H1, 2020 Summary This clinical trial report, “Emphysema Global Clinical Trials Review, H1, 2020" provides an overview of Emphysema Clinical trials scenario.This report provides top line data relating to the clinical trials on Emphysema. Report includes...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.